Bellicum is engineering high-performance cellular immunotherapies and unleashing their power against a wide range of cancers, impacting more patients than ever.

Bellicum is a clinical-stage biopharmaceutical company that is driving the future of cellular IO. They discover and develop product candidates in some of the most important areas of cellular immunotherapy, with a focus on CAR-T and CAR-NK therapies.